October 30, 2006
AACAP: Vitamin B12 Injections for Autism Show No Signs of Benefit
SAN DIEGO, Oct. 30 — Preliminary results of a small ongoing study of vitamin B12 injections for children with autism showed no signs of significant benefit, researchers reported here, but they remained hopeful.
Their hope, they noted, derived from “anecdotal reports of remarkable clinical improvements” using subcutaneous vitamin B12 (methyl cobalamin), although there have been no supporting published studies.
Vitamin B12 is an antioxidant involved in metabolism pathways for cellular methylation, which has been implicated in other neurological disorders like schizophrenia and Alzheimer’s Disease.
The researchers reported that no significant benefits have turned up yet for the 14 patients who have completed three months in the current double-blind crossover study. They found no significant differences with active versus placebo treatment for the following measures:
Clinical Global Impression Scale Improvement (P=0.4129),Peabody Picture Vocabulary Test scores (P=0.2895), and Social Communication Questionnaire verbal results (P=0.4211).A significant improvement found for nonverbal Social Communication Questionnaire scores in the vitamin B12 group compared to placebo (P=0.0309) disappeared after adjusting for multiple testing.
The researchers randomized half of the participants to six weeks of 64.5 ug/kg of subcutaneous methyl cobalamin injections every three days and the other half to a similar schedule of saline injections disguised to maintain the double-blind. For the following six weeks, the children were crossed over to the opposite group.
Diagnosis of autism was confirmed using several clinical measures including the Vineland Adaptive Behavior Scales, Autism Diagnostic Observation Schedule, and Mullen Scales of Early Learning. Patients could stay on all other treatment modalities they entered with but no additions were allowed during the trial.
Interestingly, several of the children seemed to respond well. Three of the eight participants who subsequently completed three months of open-label therapy and two of the five who have completed six months were rated “much improved” on the Clinical Global Impression Improvement scale.
“While there is a general trend toward improvement in several of the subjects, this trend does not reach group significance with this small sample size,” said Dr. Deprey.
“Autism is so heterogeneous,” she said, “you can’t expect one treatment is going to work for all kids with autism.
“The real usefulness of the study may be to indicate which patients will respond to the treatment, which is generally thought to have few side effects, commented Raum Melmed, M.D., of the Southwest Autism Research and Resource Center in Scottsdale, Ariz.
He said the study does not have a traditional design and will likely be scrutinized critically. However, he praised it as a “wonderful bridge” between research and the complimentary and alternative medicine that so many patients are using where “ground needs to be broken.”
The researchers said they plan to enroll at least 42 children in the study, which was supported by the University of California at Davis.
Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid.
ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.
The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t work. In study after repeated study: ABA (conversion therapy) doesn’t work.
What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.
The ‘cure’ for Autistics not born yet is the prevention of birth.
The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome.
This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.
Fact: You can’t cure Autistics from being Autistic.
Fact: You can’t recover an Autistic from being Autistic.
Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.
[Note: Autism is NOT a disease, but a neurodevelopmental difference and disability.]
Fact: Vaccines Do Not Cause Autism.